##gff-version 3
##sequence-region Q5MNZ9 1 446
Q5MNZ9	UniProtKB	Chain	1	446	.	.	.	ID=PRO_0000051437;Note=WD repeat domain phosphoinositide-interacting protein 1	
Q5MNZ9	UniProtKB	Repeat	3	42	.	.	.	Note=WD 1	
Q5MNZ9	UniProtKB	Repeat	47	88	.	.	.	Note=WD 2	
Q5MNZ9	UniProtKB	Repeat	92	126	.	.	.	Note=WD 3	
Q5MNZ9	UniProtKB	Repeat	131	173	.	.	.	Note=WD 4	
Q5MNZ9	UniProtKB	Repeat	177	216	.	.	.	Note=WD 5	
Q5MNZ9	UniProtKB	Repeat	222	261	.	.	.	Note=WD 6	
Q5MNZ9	UniProtKB	Repeat	304	343	.	.	.	Note=WD 7	
Q5MNZ9	UniProtKB	Motif	131	136	.	.	.	Note=Nuclear receptor interaction	
Q5MNZ9	UniProtKB	Alternative sequence	1	6	.	.	.	ID=VSP_016966;Note=In isoform 2. MEAEAA->M;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:14702039;Dbxref=PMID:14702039	
Q5MNZ9	UniProtKB	Natural variant	31	31	.	.	.	ID=VAR_024848;Note=T->I;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:15489334,ECO:0000269|PubMed:15602573;Dbxref=dbSNP:rs883541,PMID:15489334,PMID:15602573	
Q5MNZ9	UniProtKB	Natural variant	308	308	.	.	.	ID=VAR_053439;Note=R->H;Dbxref=dbSNP:rs36084378	
Q5MNZ9	UniProtKB	Mutagenesis	203	203	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	205	205	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	208	208	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. G->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	209	209	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. T->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	212	212	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. R->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	226	227	.	.	.	Note=Loss of binding to phosphoinositides%2C does not disrupt the MPR pathway. RR->AA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15020712;Dbxref=PMID:15020712	
Q5MNZ9	UniProtKB	Mutagenesis	226	226	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. R->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	227	227	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. R->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	228	228	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. G->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	251	251	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	255	255	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. T->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Mutagenesis	257	257	.	.	.	Note=Loss of binding to phosphoinositides and abolishes puncta formation. H->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23088497;Dbxref=PMID:23088497	
Q5MNZ9	UniProtKB	Sequence conflict	63	63	.	.	.	Note=V->A;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q5MNZ9	UniProtKB	Sequence conflict	249	249	.	.	.	Note=A->AA;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q5MNZ9	UniProtKB	Sequence conflict	358	358	.	.	.	Note=S->R;Ontology_term=ECO:0000305;evidence=ECO:0000305	
